View by Specialty

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

Steatohepatitis/Metabolic Liver Disease News

SPONSORED CONTENT
Save
SPONSORED CONTENT
August 06, 2024
3 min read
Save

Pemvidutide linked to ‘rapid and potent’ reduction in liver fat in MASLD at 12 weeks

Pemvidutide linked to ‘rapid and potent’ reduction in liver fat in MASLD at 12 weeks

Pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, lowered liver fat content, markers of inflammation and body weight in patients with metabolic dysfunction-associated steatotic liver disease and obesity, research showed.

SPONSORED CONTENT
July 31, 2024
2 min read
Save

Model may ‘serve as a starting point’ to identify patients with MASLD at high risk for HCC

Model may ‘serve as a starting point’ to identify patients with MASLD at high risk for HCC

A prediction model could be a “starting point” to identify patients with metabolic dysfunction-associated steatotic liver disease at high risk for hepatocellular carcinoma who may require intervention or surveillance, researchers wrote.

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

SPONSORED CONTENT
July 15, 2024
2 min watch
Save

VIDEO: GLP-1 use for MASH is ‘not black and white’; best approach may lie in the gray

VIDEO: GLP-1 use for MASH is ‘not black and white’; best approach may lie in the gray

In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that, despite the boom in glucagon-like peptide-1 agonists for diabetes and weight loss, its role in the treatment of liver disease is still up for debate.

SPONSORED CONTENT
July 15, 2024
3 min read
Save

‘Highly plausible’ GLP-1s can improve health-related QoL, economic burden of MASH

‘Highly plausible’ GLP-1s can improve health-related QoL, economic burden of MASH

Metabolic dysfunction-associated steatotic liver disease affects more than one-third of the world’s population and is associated with significant clinical and economic burden, as well as impairment of health-related quality of life.

SPONSORED CONTENT
July 15, 2024
3 min read
Save

‘Whether or not we like it,’ GLP-1s are part of hepatology, treatment of MASH

‘Whether or not we like it,’ GLP-1s are part of hepatology, treatment of MASH

To put it simply, diabetes and steatotic liver disease are joined at the hip. They are part of the same biological process that involves multiple organs, connected by the concept of metabolic flexibility — or lack thereof.

SPONSORED CONTENT
July 15, 2024
3 min read
Save

More data needed on GLP-1s, dual agonists to reach ‘optimal’ management of MASH, diabetes

More data needed on GLP-1s, dual agonists to reach ‘optimal’ management of MASH, diabetes

Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, and most patients with MASH — formerly known as NASH — experience metabolic abnormalities, including obesity.

SPONSORED CONTENT
July 15, 2024
2 min read
Save

‘Future of treating MASH’ will combine GLP-1 drugs, liver-specific medications

‘Future of treating MASH’ will combine GLP-1 drugs, liver-specific medications

Metabolic dysfunction-associated steatotic liver disease is a public health threat, affecting 30% to 38% of the adult population globally. The prevalence has risen in parallel with epidemics of obesity and type 2 diabetes.

SPONSORED CONTENT
July 15, 2024
3 min read
Save

Manage lifestyle early and aggressively to prevent, instead of treat, fatty liver

Manage lifestyle early and aggressively to prevent, instead of treat, fatty liver

Millions of dollars have been spent trying to find medications that could treat this complex disorder. The focus has been on drugs for more severe disease, as it leads to complications, and early stages have been somewhat ignored.

SPONSORED CONTENT
July 15, 2024
2 min read
Save

‘Unequivocally yes’: MASH therapies still needed despite boom in GLP-1 use in liver disease

‘Unequivocally yes’: MASH therapies still needed despite boom in GLP-1 use in liver disease

Although use of glucagon-like peptide-1 agonists for diabetes and weight loss has soared with indications now expanding into liver diseases, specifically metabolic dysfunction-associated steatohepatitis, the jury is still out on its benefit.

SPONSORED CONTENT
June 21, 2024
2 min read
Save

Nearly 62% achieve MASH resolution without worsening of fibrosis with tirzepatide

Nearly 62% achieve MASH resolution without worsening of fibrosis with tirzepatide

Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails